Electrophysiological and arrhythmogenic effects of 5-hydroxytryptamine on human atrial cells are reduced in atrial fibrillation.

PubWeight™: 1.53‹?› | Rank: Top 4%

🔗 View Article (PMC 2526346)

Published in J Mol Cell Cardiol on September 20, 2006

Authors

Davide Pau1, Antony J Workman, Kathleen A Kane, Andrew C Rankin

Author Affiliations

1: BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK. d.pau@clinmed.gla.ac.uk

Articles cited by this

Atrial L-type Ca2+ currents and human atrial fibrillation. Circ Res (1999) 3.22

The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc Res (2001) 2.41

Ionic mechanisms of electrical remodeling in human atrial fibrillation. Cardiovasc Res (1999) 2.37

Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i). Circ Res (2000) 1.88

L-type Ca2+ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. Circulation (2004) 1.85

World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Cardiovasc Res (1997) 1.80

Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res (2003) 1.78

Role of IKur in controlling action potential shape and contractility in the human atrium: influence of chronic atrial fibrillation. Circulation (2004) 1.77

Molecular basis of downregulation of G-protein-coupled inward rectifying K(+) current (I(K,ACh) in chronic human atrial fibrillation: decrease in GIRK4 mRNA correlates with reduced I(K,ACh) and muscarinic receptor-mediated shortening of action potentials. Circulation (2001) 1.76

A 5-hydroxytryptamine receptor in human atrium. Br J Pharmacol (1990) 1.76

Molecular basis of electrical remodeling in atrial fibrillation. J Mol Cell Cardiol (2000) 1.32

Peripheral 5-HT4 receptors. FASEB J (1996) 1.32

A 5-HT4-like receptor in human right atrium. Naunyn Schmiedebergs Arch Pharmacol (1991) 1.27

Cellular mechanisms of depressed atrial contractility in patients with chronic atrial fibrillation. Circulation (2001) 1.27

Do human atrial 5-HT4 receptors mediate arrhythmias? Trends Pharmacol Sci (1994) 1.24

Central 5-HT4 receptors. Trends Pharmacol Sci (1995) 1.15

5-Hydroxytryptamine causes rate-dependent arrhythmias through 5-HT4 receptors in human atrium: facilitation by chronic beta-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol (1994) 1.15

Molecular mechanisms of remodeling in human atrial fibrillation. Cardiovasc Res (2002) 1.12

Mechanisms of inactivation of L-type calcium channels in human atrial myocytes. Am J Physiol (1997) 1.10

Cardiovascular effects of intravenous infusions of 5-hydroxytryptamine in man. Br J Pharmacol Chemother (1959) 1.09

Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol (1993) 1.05

Sensitization of human atrial 5-HT4 receptors by chronic beta-blocker treatment. Circulation (1995) 1.04

Serotonin increases calcium current in human atrial myocytes via the newly described 5-hydroxytryptamine4 receptors. Mol Pharmacol (1992) 1.04

Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic. J Mol Cell Cardiol (2006) 1.03

Atrial L-type Ca2+-channel, beta-adrenorecptor, and 5-hydroxytryptamine type 4 receptor mRNAs in human atrial fibrillation. Basic Res Cardiol (2001) 1.02

Electrical remodeling in atrial fibrillation. Herz (2006) 1.01

Electrophysiological remodeling in human atrial fibrillation. Pacing Clin Electrophysiol (2003) 0.98

Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins. Mol Pharmacol (2002) 0.97

Evidence for reentry as a mechanism of cardiac arrhythmias. Rev Physiol Biochem Pharmacol (1975) 0.93

L-type calcium currents in atrial myocytes from patients with persistent and non-persistent atrial fibrillation. Basic Res Cardiol (2001) 0.93

Positive inotropic response to 5-HT in human atrial but not in ventricular heart muscle. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.93

Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic beta-adrenoceptor blockade. Br J Pharmacol (2003) 0.92

Atrial fibrillation: current understandings and research imperatives. The National Heart, Lung, and Blood Institute Working Group on Atrial Fibrillation. J Am Coll Cardiol (1993) 0.92

Cloning, pharmacological characterisation and tissue distribution of a novel 5-HT4 receptor splice variant, 5-HT4(i). Naunyn Schmiedebergs Arch Pharmacol (2004) 0.90

Beta-blockers as antiarrhythmic agents. Handb Exp Pharmacol (2006) 0.90

5-hydroxytryptamine and atrial fibrillation: how significant is this piece in the puzzle? J Cardiovasc Electrophysiol (2003) 0.86

Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes. J Mol Cell Cardiol (2005) 0.83

Role of calcium in arrhythmogenesis. Circulation (1989) 0.83

Pharmacological modulation of the hyperpolarization-activated current (I f) in human atrial myocytes: focus on G protein-coupled receptors. J Mol Cell Cardiol (2005) 0.81

The indirect negative inotropic effect of carbachol in beta1-adrenoceptor antagonist-treated human right atria. Eur J Pharmacol (2003) 0.81

Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. J Pharmacol Exp Ther (2005) 0.80

High efficiency activation of L-type Ca2+ current by 5-HT in human atrial myocytes. Receptors Channels (2004) 0.78

Articles by these authors

Human atrial action potential and Ca2+ model: sinus rhythm and chronic atrial fibrillation. Circ Res (2011) 1.82

Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling. Cardiovasc Res (2003) 1.78

Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm (2008) 1.72

Post-operative atrial fibrillation is influenced by beta-blocker therapy but not by pre-operative atrial cellular electrophysiology. J Cardiovasc Electrophysiol (2006) 1.65

Characterisation of the Na, K pump current in atrial cells from patients with and without chronic atrial fibrillation. Cardiovasc Res (2003) 1.62

Cellular bases for human atrial fibrillation. Heart Rhythm (2008) 1.25

Targeting atrioventricular differences in ion channel properties for terminating acute atrial fibrillation in pigs. Cardiovasc Res (2010) 1.05

Targeting sphingosine-1-phosphate signalling for cardioprotection. Curr Opin Pharmacol (2008) 1.04

Anti-adrenergic effects of endothelin on human atrial action potentials are potentially anti-arrhythmic. J Mol Cell Cardiol (2006) 1.03

Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? J Am Coll Cardiol (2003) 1.02

Electrophysiological effects of 5-hydroxytryptamine on isolated human atrial myocytes, and the influence of chronic beta-adrenoceptor blockade. Br J Pharmacol (2003) 0.92

A web-based tool for teaching pharmacy practice competency. Am J Pharm Educ (2010) 0.85

Endothelin and the ischaemic heart. Curr Vasc Pharmacol (2005) 0.85

Junctional rhythm--a suitable surrogate endpoint in catheter ablation of atrioventricular nodal reentry tachycardia? Pacing Clin Electrophysiol (2005) 0.85

Remodelling of human atrial K+ currents but not ion channel expression by chronic β-blockade. Pflugers Arch (2011) 0.82

Adrenomedullin acts via nitric oxide and peroxynitrite to protect against myocardial ischaemia-induced arrhythmias in anaesthetized rats. Br J Pharmacol (2006) 0.81

Apex-to-base dispersion of refractoriness underlies the proarrhythmic effect of hypokalaemia/hypomagnesaemia in the rabbit heart. J Electrocardiol (2002) 0.81

Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br J Pharmacol (2010) 0.80

IP(3)R-mediated Ca(2+) release is modulated by anandamide in isolated cardiac nuclei. J Mol Cell Cardiol (2008) 0.80

Chronic myocardial infarction promotes atrial action potential alternans, afterdepolarizations, and fibrillation. Cardiovasc Res (2013) 0.80

Electrophysiological effects of prucalopride, a novel enterokinetic agent, on isolated atrial myocytes from patients treated with beta-adrenoceptor antagonists. J Pharmacol Exp Ther (2005) 0.80

Duration of heart failure and the risk of atrial fibrillation: different mechanisms at different times? Cardiovasc Res (2009) 0.79

Sarafotoxin 6c (S6c) reduces infarct size and preserves mRNA for the ETB receptor in the ischemic/reperfused myocardium of anesthetized rats. J Cardiovasc Pharmacol (2004) 0.77

The assessment of autonomic function in chronic atrial fibrillation: description of a non-invasive technique based on circadian rhythm of atrioventricular nodal functional refractory periods. Europace (2006) 0.77

Activation of protease activated receptor-2 induces delayed cardioprotection in anesthetized mice. Cardiovasc Drugs Ther (2009) 0.76

Do hypoxemia or hypercapnia predispose to atrial fibrillation in breathing disorders, and, if so, how? Heart Rhythm (2010) 0.75

Electrophysiological and haemodynamic effects of endothelin ETA and ETB receptors in normal and ischaemic working rabbit hearts. Br J Pharmacol (2005) 0.75

Localization of accessory pathways in the Wolff-Parkinson-White pattern--physician versus computer interpretation of the same algorithm. Pacing Clin Electrophysiol (2007) 0.75

Assessing stroke risk in patients with AF. Practitioner (2007) 0.75